. 2014 Sep 8;14(12):1259–1270. doi: 10.1016/S1473-3099(14)70821-7

Table 1.

Representative antiviral combinations that have been studied or are presently in trials, by study type

	Drugs tested	Target population
Pharmacokinetic interactions	Oral oseltamivir + oral amantadine (NCT00416962) Oral oseltamivir + oral favipiravir (unpublished) Intravenous peramivir + oral rimantadine⁴³ Intravenous peramivir + oral oseltamivir⁴³ Intravenous zanamivir + oral oseltamivir⁴⁴ Oral amantadine + oral ribavirin + oral oseltamivir (NCT00867139)	Healthy volunteers Healthy volunteers Healthy volunteers Healthy volunteers Healthy volunteers Healthy volunteers
Completed controlled trails of clinical efficacy	Oral rimantadine + nebulised zanamivir⁴ Oral oseltamivir + inhaled zanamivir⁴² Oral oseltamivir + pH1N1 convalescent plasma⁴⁵ Oral oseltamivir + pH1N1 hyperimmune globulin (NCT01617317) Oral oseltamivir + maxingshigan/yinqiaosan (NCT00935194) Oral oseltamivir + sirolimus + corticosteroids⁴⁶ Oral amantadine + ribavirin + oseltamivir (TCAD; NCT01617317)	Hospitalised adults Ambulatory adults Critically ill patients Critically ill patients Ambulatory adults Critically ill patients Critically ill patients
Continuing randomised controlled trials of clinical efficacy	Oral oseltamivir + convalescent plasma or hyperimmune globulin (NCT01052480) Oral amantadine + ribavirin + oseltamivir (TCAD; NCT01227967) Oseltamivir + nitazoxanide (NCT01610245)	Hospitalised adults High-risk outpatients Ambulatory adults

TCAD= triple combination antiviral drug.